logomap中文|EN

A Global Foot Print

Phagelux AgriHealth

Phagelux AgriHealth utilizes phages, other biologics, and related or enabling technologies to create novel antibacterial products and solutions. These products address bacterial problems across multiple segments of agriculture, particularly targeting antibiotic resistant strains of bacteria. Phagelux AgriHealth has research labs and manufacturing facilities in North America and China. The Company aims to be a leading global Bio-agricultural company.

Phagelux AgriHealth has four franchises: crop sciences, animal health, food safety and feed additives. The Company currently sells five crop sciences products, three food safety products and five animal health products (not all products available in all markets yet). Additional products are in development or under regulatory review.

Phagelux AgriHealth

Management

Mark Engel

Mark Engel

Chairman and CEO

30+ years experience in building life sciences companies. Investor in life sciences and agricultural
companies.

Matthew  Tebeau

Matthew Tebeau

COO

MA from Harward University. 10+ years experience in leading strategic and BD process in global phage company.

Tyler Homer

Tyler Homer

COO of OmniLytics

MBA. Rich experience in phage product registration and project cooperation.

Andy Chen

Andy Chen

VP, China Operations

Extensive experience in financial management, including IPO process.

Dr. Ryan Bringhurst

Dr. Ryan Bringhurst

VP, Agricultural Research

Ph.D in Microbiology. 10 years developing phage products, with focus on food safety and treatment of agricultural diseases.

Ryan Benson

Ryan Benson

Director of Sales and Marketing - US

Extensive experience in life sciences products sales and market management.

Dr. Xuling Xu

Dr. Xuling Xu

CTO - China

Ph.D in Molecular biology. 10+ years experience in managing phage product development and creating new phage platforms.

Dr. Yu Cong

Dr. Yu Cong

Director of Sales and Marketing - China

Ph.D in Agronomy. Strong expertise in horticultural science and plant nutrition. Industry leader in phage product development and related technologies.

Joachim Hasenmaier

Joachim Hasenmaier

Independent Director

Currently serves as Chairman, Director, or investor for multiple agriculture companies. Previously member of board of Managing Directors of BI and heading BI’s 4.5b+ Euro animal health division.

Dirk Ehle

Dirk Ehle

Independent Director

Currently serves as Board Member, Investor and Advisor to multiple companies with a focus on life sciences. Previously Executive VP - President of Elanco Animal Health Europe, Head of Bayer Animal Health.

History

2013.11

Founded and invested by the Management and Wuxi AppTec.

2014.2

First research lab established in Nanjing.

2015.7

Acquisition of Omnilytics, to obtain R&D and production capacity in North America and to start to implement a global strategy

2016.1

Round A financing completed.

2018.7

Round B financing completed.

2019.10

Spun off from Phagelux HumanHealth.

2020.6

Bring in strategic investor Wuxi Guolian.

icon
icon

R&D Centers

  • R&D Center in Nanjing, China
    R&D Center in Nanjing, China
    R&D Center in Nanjing, China

    R&D Center in Nanjing, China

    1,500 SM facility, which includes small scale manufacturing facility. 6 products from this facility have already been registered in China, and another 8 are under development or regulatory review. The facility is primarily working on phages for animal health, including disinfectants, feeds and medicines.
  • R&D Center in SLC, Utah
    R&D Center in SLC, Utah
    R&D Center in SLC, Utah

    R&D Center in SLC, Utah

    750 SM research lab including Biosafety Level 2 Laboratory, with large private library of characterized phages and bacteria. The facility is primarily working on the development of crop science and food safety products and currently working on 8 new products and supporting 7 established products.